What is the projected growth of the breast cancer liquid biopsy market?
The breast cancer liquid biopsy market is expected to grow at a CAGR of 15.3% from 2023 to 2030, driven by rising cancer rates and the demand for minimally invasive testing.
Who are the major players in the breast cancer liquid biopsy market?
QIAGEN, F. Hoffmann-La Roche, Bio-Rad Laboratories, and Guardant Health are some of the major players in the global breast cancer liquid biopsy market.
What are the benefits of using liquid biopsy for breast cancer?
Liquid biopsy offers a non-invasive, simple, and cost-effective way to diagnose and monitor breast cancer compared to traditional tissue biopsies.
What are the different types of circulating biomarkers used in liquid biopsy?
Circulating cell-free DNA (cfDNA), circulating tumor cells (CTCs), and extracellular vesicles are some of the main circulating biomarkers used in liquid biopsy for breast cancer.